Premium
Survival and graft‐versus‐host disease in patients receiving peripheral stem cell compared to bone marrow transplantation from HLA ‐matched related donor: retrospective analysis of 334 consecutive patients
Author(s) -
Campregher Paulo Vidal,
Hamerschlak Nelson,
Colturato Vergilio Antonio Renzi,
Mauad Marcos Augusto,
Souza Mair Pedro,
Bouzas Luis Fernando da Silva,
Tavares Rita de Cássia B.,
Barros José Carlos,
Chiattone Ricardo,
Paz Alessandra,
Silla Lucia,
Vigorito Afonso Celso,
Miranda Eliane,
Funke Vaneuza Araújo Moreira,
Flowers Mary Evelyn
Publication year - 2015
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12508
Subject(s) - medicine , cumulative incidence , incidence (geometry) , hematopoietic stem cell transplantation , graft versus host disease , bone marrow , gastroenterology , transplantation , retrospective cohort study , surgery , human leukocyte antigen , stem cell , immunology , antigen , physics , biology , optics , genetics
Objectives The objective of this study was to compare the major transplant outcomes between patients receiving hematopoietic stem cell transplantation ( HSCT ) from bone marrow ( BM ) or peripheral blood stem cells ( PBSC ). Methods All consecutive HSCT patients using BM or PBSC from an HLA ‐matched related donors for haematological malignancies after high intensity conditioning at seven Brazilian transplant centres between January 2008 and December 2009 were retrospectively evaluated. Results In the study period, 334 patients were treated in the centres and included in the evaluation. The cumulative incidence of grades II – IV and III – IV acute graft‐versus‐host disease ( GVHD ) at one year was 36.7% and 9.7% for BM recipients and 34.4% and 15.1% for PBSC recipients, respectively (not statistically different). The cumulative incidence of chronic GVHD at three years was 53.7% and 79.8% ( HR 1.93; 95% CI 1.38–2.69, P < 0.001) for BM and PBSC , respectively. Median overall survival was 2.85 and 2.39 years for BM and PBSC recipients, respectively ( HR 1.19; 95% CI , 0.84–1.68, P = 0.34). Conclusions Our results confirm previous findings of increased chronic GVHD incidence in patients receiving PBSC when compared to patients receiving BM as the graft source in HSCT . Acute GVHD incidence, progression‐free survival and overall survival were not different between the groups.